IL165935A0 - Use of vasopeptidase inhibitors in the treatment of nephropathy - Google Patents

Use of vasopeptidase inhibitors in the treatment of nephropathy

Info

Publication number
IL165935A0
IL165935A0 IL16593503A IL16593503A IL165935A0 IL 165935 A0 IL165935 A0 IL 165935A0 IL 16593503 A IL16593503 A IL 16593503A IL 16593503 A IL16593503 A IL 16593503A IL 165935 A0 IL165935 A0 IL 165935A0
Authority
IL
Israel
Prior art keywords
nephropathy
treatment
vasopeptidase inhibitors
vasopeptidase
inhibitors
Prior art date
Application number
IL16593503A
Other languages
English (en)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of IL165935A0 publication Critical patent/IL165935A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16593503A 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy IL165935A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen

Publications (1)

Publication Number Publication Date
IL165935A0 true IL165935A0 (en) 2006-01-15

Family

ID=29795983

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16593503A IL165935A0 (en) 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy
IL16593504A IL165935A (en) 2002-06-28 2004-12-22 Vasopeptidase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL16593504A IL165935A (en) 2002-06-28 2004-12-22 Vasopeptidase inhibitors

Country Status (38)

Country Link
US (2) US6930103B2 (sr)
EP (1) EP1519732B1 (sr)
JP (1) JP4564354B2 (sr)
KR (1) KR101072235B1 (sr)
CN (1) CN100366254C (sr)
AR (1) AR040343A1 (sr)
AT (1) ATE548040T1 (sr)
AU (1) AU2003280440B2 (sr)
BR (1) BR0312250A (sr)
CA (1) CA2490277C (sr)
CR (1) CR7667A (sr)
CY (1) CY1112905T1 (sr)
DE (1) DE10229180A1 (sr)
DK (1) DK1519732T3 (sr)
EC (1) ECSP045513A (sr)
ES (1) ES2383889T3 (sr)
HN (1) HN2003000193A (sr)
HR (1) HRP20041212B1 (sr)
IL (2) IL165935A0 (sr)
MA (1) MA27281A1 (sr)
MX (1) MXPA04012230A (sr)
NO (1) NO334811B1 (sr)
NZ (1) NZ537480A (sr)
OA (1) OA12871A (sr)
PA (1) PA8576501A1 (sr)
PE (1) PE20040582A1 (sr)
PL (1) PL218070B1 (sr)
PT (1) PT1519732E (sr)
RS (1) RS52478B (sr)
RU (1) RU2336080C2 (sr)
SI (1) SI1519732T1 (sr)
SV (1) SV2004001560A (sr)
TN (1) TNSN04262A1 (sr)
TW (1) TWI326215B (sr)
UA (1) UA82845C2 (sr)
UY (1) UY27869A1 (sr)
WO (1) WO2004002492A1 (sr)
ZA (1) ZA200409382B (sr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
WO1992015558A1 (fr) * 1991-03-01 1992-09-17 Zeria Pharmaceutical Co., Ltd. Derive d'indane et antagoniste de thromboxane le contenant
RU2098411C1 (ru) * 1991-08-02 1997-12-10 Иституто Лусо Фармако д Италия С.п.А. Производные пиримидина, способ их получения, фармацевтическая композиция на их основе
ATE155143T1 (de) * 1991-09-27 1997-07-15 Merrell Pharma Inc 2-substituierte indan-2-mercaptoacetylamid- verbindungen mit enkephalinase und ace- hemmwirkung
DE69317764T2 (de) * 1992-02-14 1998-07-30 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
PT751783E (pt) * 1994-03-24 2000-05-31 Merrell Pharma Inc Derivados aminoacetilmercapto hipocolesterolemicos antiateroscleroticos e hipotrigliceridemicos
CA2224451A1 (en) * 1995-06-30 1997-01-23 Merck & Co., Inc. Method of treating renal disease using an ace inhibitor and an aii antagonist
CZ294485B6 (cs) 1995-12-27 2005-01-12 Welfide Corporation Léčivo pro prevenci a léčbu diabetických komplikací
HUP0203326A3 (en) * 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
ATE286898T1 (de) * 2001-04-12 2005-01-15 Aventis Pharma Gmbh Mercaptoacetylamid-derivate, prozess zur herstellung sowie deren verwendung
WO2003013434A2 (en) * 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace

Also Published As

Publication number Publication date
CA2490277A1 (en) 2004-01-08
DE10229180A1 (de) 2004-01-29
SI1519732T1 (sl) 2012-05-31
NO20050425L (no) 2005-01-25
EP1519732B1 (en) 2012-03-07
JP4564354B2 (ja) 2010-10-20
PL218070B1 (pl) 2014-10-31
ZA200409382B (en) 2006-01-25
ATE548040T1 (de) 2012-03-15
AU2003280440B2 (en) 2009-07-16
RU2005102087A (ru) 2005-07-10
NZ537480A (en) 2005-11-25
PT1519732E (pt) 2012-05-22
KR20050013642A (ko) 2005-02-04
ES2383889T3 (es) 2012-06-27
US20040058911A1 (en) 2004-03-25
NO334811B1 (no) 2014-06-02
DK1519732T3 (da) 2012-06-18
HN2003000193A (es) 2004-10-27
JP2005533815A (ja) 2005-11-10
EP1519732A1 (en) 2005-04-06
CR7667A (es) 2005-06-16
CN100366254C (zh) 2008-02-06
HRP20041212B1 (hr) 2013-06-30
US20050171090A1 (en) 2005-08-04
OA12871A (en) 2006-09-15
RS52478B (sr) 2013-02-28
TW200406214A (en) 2004-05-01
ECSP045513A (es) 2005-03-10
AR040343A1 (es) 2005-03-30
TNSN04262A1 (en) 2007-03-12
CY1112905T1 (el) 2016-04-13
MXPA04012230A (es) 2005-02-25
RS100704A (sr) 2007-02-05
KR101072235B1 (ko) 2011-10-12
US7514423B2 (en) 2009-04-07
UY27869A1 (es) 2003-12-31
PA8576501A1 (es) 2004-02-07
RU2336080C2 (ru) 2008-10-20
WO2004002492A1 (en) 2004-01-08
SV2004001560A (es) 2004-02-26
PL372992A1 (en) 2005-08-08
CN1665512A (zh) 2005-09-07
UA82845C2 (en) 2008-05-26
BR0312250A (pt) 2005-04-26
AU2003280440A1 (en) 2004-01-19
IL165935A (en) 2010-12-30
PE20040582A1 (es) 2004-10-18
HRP20041212A2 (en) 2005-06-30
CA2490277C (en) 2011-11-01
HK1079435A1 (zh) 2006-04-07
MA27281A1 (fr) 2005-04-01
TWI326215B (en) 2010-06-21
US6930103B2 (en) 2005-08-16

Similar Documents

Publication Publication Date Title
IL166780A0 (en) Use of ikappab-kinase inhibitors in pain therapy
AU2003284242A8 (en) Methods and compositions for use in treating cancer
AU2003293376A8 (en) Anti-angiogenic compounds and their use in cancer treatment
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
IL172471A0 (en) Gsk-3 inhibitors and uses thereof
AU2003213768A8 (en) Use of benzimidazole analogs in the treatment of cell proliferation
AU2003281978A8 (en) Compounds for use in treating obesity
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
AU2003213144A1 (en) Alkylating agent combinations in the treatment of cancer
IL172316A0 (en) Novel compounds and their use in therapy
ZA200800434B (en) Benzoquinazoline derivatives and their use in treating bone disorders
GB0324761D0 (en) Use of compounds in therapy
ZA200410409B (en) Use of thio-oxindole derivatives in treatment of hormonerelated conditions
EP1515725A4 (en) USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED ILLNESSES
AU2003212634A8 (en) Compounds useful in the treatment of cancer
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
IL180138A0 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinol (pi) 3-kinase inhibitors and their use in the treatment of cancer
GB0207411D0 (en) Azole compounds and their therapeutic use
GB0212405D0 (en) Composition and its therapeutic use
PL380189A3 (pl) Azolidynokarbonitryle i ich zastosowanie jako inhibitory DPP-IV
AU2003206945A8 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
SG110107A1 (en) Compound and use in treatment
HRP20041212A2 (en) Use of vasopeptidase inhibitors in the treatment of nephropathy
EP1671648A4 (en) PREVENTION AND TREATMENT OF GVHD